Although FLG and VCAN are less well explored in HER2+ BC, FLG mutations have been associated with higher tumor mutation load and immunogenicity in gastric cancer[36], while VCAN alterations have been linked to prostate cancer progression and docetaxel resistance[37,38]. Here, ERBB2 is linked to prostate carcinoma.